Supplementary Data from Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma

Shared by

Preprint 2024 en

Authors

Abstract

1 min read

<p>Supplemental Materials and Methods, Results, Tables and Figures</p>

No comments yet. Be the first to comment.

Public, signed peer feedback on this preprint.

No reviews yet.